Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

80° Partly Cloudy
- Plymouth, IN (46563)
  Today
  
  Thunderstorms during the evening will give way to cloudy skies after midnight. Low 63F. Winds NNE at 5 to 10 mph. Chance of rain 80%..
  
  Tonight
  
  Thunderstorms during the evening will give way to cloudy skies after midnight. Low 63F. Winds NNE at 5 to 10 mph. Chance of rain 80%.
  
  Updated: September 17, 2026 @ 6:22 pm
- Full Forecast

Site search

News
- Local News
- The Leader
Sports
Obituaries
Classifieds
Archives
Best of 2026
Pilot News E-Edition
Culver Citizen

Recent Quotes

View Full List

My Watchlist

Adm Tronics Unltd Inc

American Rare Earths Ltd

Ameritrust Financial Technologies Inc

Anadarko Petroleum

AppFolio, Inc. - Class A Common Stock

Axis Technologies Group Inc

Bank of N.T. Butterfield & Son Limited (The) Voting Ordinary Shares

Bright Minds Biosciences Inc

Brookfield Infra Partners LP Pref Ser 11

Brookfield Renewable Corporation Brookfield Renewable Corporation Class A

Bruker Corporation - 6.375% Mandatory Convertible Preferred Stock, Series A

Camtek Ltd. - Ordinary Shares

Canadian Tire Ltd

China New Energy Group Co.

Consumer Portfolio Services, Inc. - Common Stock

Copper Giant Res Corp

Cornerstone Community Bancorp

Deutsche Lufthansa Ag

Eco Wave Power Global AB (publ) - American Depositary Shares

Entourage Health Corp

Enveric Biosciences, Inc. - Common Stock

F3 Uranium Corp

Field Trip Health Ltd. - Common Shares

Fundamental Global Inc. - Common Stock

Golden Matrix Group, Inc. - Common Stock

Hero Technologies Inc

KnowBe4, Inc. - Class A Common Stock

Lancaster Colony Corporation - Common Stock

Mednow Inc

Microbix Biosystems Inc

Miller Industries, Inc. Common Stock

Mixed Martial Arts Group Limited Ordinary Shares

MoneyLion Inc. Class A Common Stock

Monroe Capital Corporation - Closed End Fund

Mural Oncology plc - Ordinary Shares

NEOS Bitcoin High Income ETF

Orsu Metals Corp

PMV Pharmaceuticals, Inc. - Common Stock

Putnam International Stock ETF

Sharecare, Inc. - Class A Common Stock

Sharps Technology Inc. - Common Stock

SmileDirectClub, Inc. - Common Stock

Spire Global, Inc. Class A Common Stock

Stamps.com Inc. - Common Stock

Star Equity Holdings, Inc. - 10% Series A Cumulative Perpetual Preferred Stock

Streamline Health Solutions, Inc. - Common Stock

Sturgis Bancorp Inc

TELUS International (Cda) Inc. Subordinate Voting Shares

The Bank of New York Mellon Corporation Common Stock

Tokyo Tatemono Company Ltd

Tortoise Sustainable and Social Impact Term Fund Common shares of beneficial

Treatment.com Ai Inc

United Community Banks, Inc. Common Stock

VIX Short-Term Futures ETF

Vanguard Communication Services ETF

View, Inc. - Class A Common Stock

Virgin Orbit Holdings, Inc. - Common Stock

Waitr Holdings Inc. - Common Stock

Waterdrop Inc. American Depositary Shares (each representing the right to

Well Health Technologies Corp

Westlake Chemical

WideOpenWest, Inc. Common Stock

Xeriant Inc

Edit Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

10.45 UNCHANGED

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Today's US Session Top Gainers and Losers: TNONW and CENN Lead ↗

November 04, 2026

Via Chartmill

Top U.S. Stock Movers: Nov. 4, 2026 Gainers and Losers ↗

November 04, 2026

Via Chartmill

Syndax (SNDX) Q3 2026 Earnings Call Transcript ↗

November 02, 2026

Revenue surged 82% year-over-year as Revuforj and Niktimvo drive commercial momentum.

Via The Motley Fool

Topics Earnings

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Drop as Q2 Revenue and EPS Miss Estimates ↗

August 04, 2026

Via Chartmill

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Stock Slides After Q1 Revenue Misses Street Forecasts Despite 224% Growth ↗

April 30, 2026

Via Chartmill

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗

March 26, 2026

Via Chartmill

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗

February 26, 2026

Via Chartmill

What Syndax Pharmaceuticals (SNDX) Said on Its Q3 Earnings Call ↗

November 02, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) reported third-quarter 2026 total revenue of $83.3 million, an 82% increase from the prior-year period, as sales of its Revuforj leukemia treatment and...

Via MarketBeat

Topics Earnings

What's going on in today's after hours session ↗

October 12, 2026

Via Chartmill

Syndax (SNDX) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Revenue surged 92% year-over-year to $72.8 million, driven by Revuforj and Niktimvo.

Via The Motley Fool

Topics Earnings

Syndax Pharmaceuticals Q2 Earnings Call Highlights ↗

August 04, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic...

Via MarketBeat

Topics Earnings

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Syndax Pharmaceuticals's Earnings Outlook ↗

October 31, 2025

Via Benzinga

Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push ↗

July 14, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) used a company R&D event to outline expansion plans for its approved medicines Revuforj and Niktimvo while introducing two pipeline assets aimed at non-small cell...

Via MarketBeat

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Via The Motley Fool

Topics Regulatory Compliance

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗

October 24, 2025

Via Stocktwits

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

Via The Motley Fool

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Via The Motley Fool

Topics Regulatory Compliance

Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Syndax (SNDX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

Why Is Syndax Stock Down Today? ↗

October 24, 2025

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration.

Via Benzinga

Where Syndax Pharmaceuticals Stands With Analysts ↗

October 16, 2025

Via Benzinga

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗

September 04, 2025

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Via Benzinga

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 04, 2025

Via Benzinga

Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗

September 04, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Search
Weather

www.thepilotnews.com
218 N. Michigan
Plymouth, IN 46563
Phone: 574-936-3101
Email: webmaster@thepilotnews.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Plymouth, IN (46563)

Today

Tonight

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

Headline News about Syndax Pharmaceuticals, Inc. - Common Stock

Sections

Services